WW International Inc (WW) Stock Price Up 3.34% on Jul 18: Analysts Forecast Downside of 97.24%.

Shares of WW International Inc (WW) surged 3.34% to $36.17 on July 18, with an intraday high of $36.99. The stock is 22.96% below its 52-week high and 30,761.77% above its 52-week low. Analysts forecast an average target price of $1.00, implying a 97.24% downside from the current price. The estimated GF Value for WW International Inc in one year is $2.43, suggesting a 93.28% downside from the current price.

Shares of WW International Inc. (WW), formerly known as WeightWatchers, surged 3.34% to $36.17 on July 18, 2025, reaching an intraday high of $36.99. The stock is currently 22.96% below its 52-week high and 30,761.77% above its 52-week low. Analysts forecast an average target price of $1.00, indicating a 97.24% downside from the current price. The estimated GF Value for WW International Inc. in one year is $2.43, suggesting a 93.28% downside from the current price.

WW International Inc. emerged from Chapter 11 bankruptcy in mid-2025 after successfully negotiating a prepackaged restructuring that eliminated approximately $1.15 billion in debt, leaving the company with about $465 million in new secured debt due by 2030 and $175 million in liquidity [1]. The company's stock has since shown impressive growth, gaining around 42% over the past month.

The company's turnaround can be attributed to a strategic reorganization and leadership overhaul. New CEO Tara Comonte and her team have overhauled the leadership, hiring Dr. Kim Boyd as Chief Medical Officer and refreshing the board with healthcare veterans, including former Eli Lilly and Company (LLY) executive Mike Mason [2]. This pivot is a clear reaction to the rise of GLP-1 obesity drugs, which helped trigger six straight years of revenue declines and hundreds of millions in losses for WW.

With its new strategy, WW International Inc. is focusing on a broader care model anchored by a new menopause-focused program. The company has largely abandoned lower-cost compounding of GLP-1s in favor of insurance-backed Rx models. This shift marks a significant change from the company's traditional dieting approach and positions it as a health technology provider.

Despite the stock's recent gains, analysts remain cautious. The valuation seems too high compared to peers, and the company's future remains uncertain. However, the new leadership's clear vision and the integrated women's health initiative could be the major growth catalysts for the company.

References:

[1] https://stockanalysis.com/stocks/ww/
[2] https://seekingalpha.com/article/4801152-weightwatchers-menopause-healths-comeback